Drug intelligence / Profile preview

ioforminol

Development stage: Phase 2
Lead developer: GE Healthcare
Modality: Small Molecules
Administration: Intravenous, Intra-arterial, Intracoronary

Overview

Ioforminol (GE-145) is a non-ionic, dimeric, iso-osmolar iodinated contrast medium (IOCM) developed by GE HealthCare for diagnostic imaging applications, including contrast-enhanced computed tomography (CECT) and coronary angiography. As an iso-osmolar agent, ioforminol is designed to be chemically stable and provide high radiographic contrast while minimizing the risk of contrast-induced nephropathy (CIN) and other adverse events, particularly in vulnerable populations such as elderly patients or those with pre-existing renal impairment, diabetes, or heart failure. The molecule contains multiple iodine atoms which attenuate X-rays, thereby enhancing the visualization of blood vessels and soft tissues during medical imaging procedures.

Other names: GE-145GE145GE 145

Beyond the preview

Go deeper on ioforminol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ioforminol.

Explore the full profile